Linked Life Data

9768824

Source:http://linkedlifedata.com/resource/pubmed/id/9768824

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Suppl 10
pubmed:dateCreated
1998-10-20
pubmed:abstractText
Dexrazoxane prevents the dose-limiting cardiotoxicity of the anthracyclines without reducing their antitumor efficacy and without new adverse side effects. Dexrazoxane reduces the severity of gastrointestinal symptoms of the anthracycline containing combination doxorubicin, 5-fluorouracil, cyclophosphamide and most surprisingly and importantly, dexrazoxane increases the median survival time of advanced breast cancer responders to the doxorubicin, 5-fluorouracil, cyclophosphamide regimen. The median survival time is doubled as compared to controls to nearly 3 years.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
48-54
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Overview and historical development of dexrazoxane.
pubmed:affiliation
Windleshaw House, Withyham, East Sussex, England.
pubmed:publicationType
Journal Article, Review